Earnings ·
ADMA Biologics reports Q3 revenue of $141.1M, GAAP net income of $49.9M
ADMAAdma Biologics, Inc.
ADMA Biologics reported third-quarter 2026 total revenue of $141.1 million, a 5% increase year-over-year and 13% sequentially. ASCENIV revenue grew 31% to $124.7 million, while BIVIGAM revenue declined to $15.4 million due to competitive pricing pressures. GAAP net income rose 37% to $49.9 million, or $0.22 per share, driven by expanding gross margins of 71%. The company reiterated its full-year revenue guidance of at least $530 million and increased its adjusted earnings outlook. Additionally, ADMA announced constructive FDA feedback on its SG-001 pre-IND meeting package and continued share repurchases under its authorized program. ADMA Biologics is a U.S.-based biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics.